Appointment of Steven Holtzman as independent board member
Molecular Partners AG announced today the appointment of Steven H. Holtzman as an independent non-executive member of its board of directors.
“We are pleased to welcome Steven to the board of Molecular Partners,” said Jörn Aldag, Chairman of the Board of Directors at Molecular Partners. “He brings with him a wealth of experience in building and managing successful biotech companies at a time where Molecular Partners is significantly progressing its broad clinical and preclinical pipeline and important partnerships. He will prove invaluable to Molecular Partners in supporting many of our decisions as the company further matures.”
Mr. Holtzman brings considerable experience to the board of Molecular Partners. He is currently serving as Executive Vice President, Corporate Development on the Executive Committee of Biogen Idec. Prior to that, Steven Holtzman was a founder, initially Chief Executive Officer and Chairman of the Board of Infinity Pharmaceuticals, Inc., Chief Business Officer at Millennium Pharmaceuticals, Inc. and a founder and member of the Board of Directors and Executive Vice President of DNX Corporation.
Steven Holtzman is a board member or trustee of the Biotechnology Industry Organization (BIO), PMV Pharma (a private biotechnology company), the Berklee College of Music, and the Board of Overseers of the Isabella Stewart Gardner Museum. He used to serve as a presidential appointee to the US National Bioethics Advisory Commission. Steven Holtzman received his B.A. from Michigan State University and B.Phil. graduate degree from Oxford University which he attended as a Rhodes Scholar.
“I am delighted to join Molecular Partners, one of the most exciting biotech stories in Europe,” added Steven Holtzman. “DARPins represent a new powerful class of small protein therapies, and the stage is set to continue to build on the success laid out in a strong clinical and preclinical pipeline and several impressive alliances. I look forward to supporting Molecular Partners in these exciting times and to being part of its continued success.”